UA107141U - METHOD OF TREATMENT OF OPIATES OF OPIATE ABSTINENT SYNDROME - Google Patents
METHOD OF TREATMENT OF OPIATES OF OPIATE ABSTINENT SYNDROMEInfo
- Publication number
- UA107141U UA107141U UAU201511088U UAU201511088U UA107141U UA 107141 U UA107141 U UA 107141U UA U201511088 U UAU201511088 U UA U201511088U UA U201511088 U UAU201511088 U UA U201511088U UA 107141 U UA107141 U UA 107141U
- Authority
- UA
- Ukraine
- Prior art keywords
- tablet
- opiate
- opiates
- treatment
- belalgin
- Prior art date
Links
- 229940127240 opiate Drugs 0.000 title abstract 3
- 208000011580 syndromic disease Diseases 0.000 title 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 abstract 2
- 229960000836 amitriptyline Drugs 0.000 abstract 2
- 230000000202 analgesic effect Effects 0.000 abstract 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 abstract 2
- 230000003153 cholinolytic effect Effects 0.000 abstract 2
- 108010087765 Antipain Proteins 0.000 abstract 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
- 206010048010 Withdrawal syndrome Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 239000008188 pellet Substances 0.000 abstract 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Спосіб лікування проявів опіатного абстинентного синдрому, котрий включає комбіноване використання препаратів белалгіну, амітриптиліну та аміназіну у таблетованій формі, який відрізняється тим, що холінолітик та анальгетик белалгін використовується як вегетоактивна та протибольова складова частина медикаментозного комплексу разом з холінолітично активними антидепресантом амітриптиліном та нейролептиком аміназином, котрі, підсилюючи позитивний холінолітичний та протибольовий вплив белалгіну, також допомагають ліквідувати порушення настрою та сну, та при цьому белалгін застосовується у вигляді таблетованого стандартного препарату, який дається хворому три рази на добу - вранці, в обід та ввечері по одній таблетці, амітриптилін також застосовується двічі на добу у вигляді таблетованого стандартного препарату в дозі по 25 мг в обід та на ніч - по одній таблетці, а аміназин дається один раз на ніч у кількості двох таблеток по 25 мг.A method of treating manifestations of opiate withdrawal syndrome, comprising the combined use of pellets of belgin, amitriptyline and aminazine, characterized in that cholinolytic and analgesic belalgin is used as a vegetative and anti-pain component of anticancer drugs by enhancing the positive cholinolytic and analgesic effects of belgin, they also help to eliminate the disorder In this case, belalgin is used as a standard tablet, which is given to the patient three times a day - in the morning, at lunch and in the evening, one tablet, amitriptyline is also administered twice daily as a standard 25 mg tablet. one tablet at a time and at night and aminazine is given once a night in the amount of two 25 mg tablets.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAU201511088U UA107141U (en) | 2015-11-12 | 2015-11-12 | METHOD OF TREATMENT OF OPIATES OF OPIATE ABSTINENT SYNDROME |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAU201511088U UA107141U (en) | 2015-11-12 | 2015-11-12 | METHOD OF TREATMENT OF OPIATES OF OPIATE ABSTINENT SYNDROME |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA107141U true UA107141U (en) | 2016-05-25 |
Family
ID=56292172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAU201511088U UA107141U (en) | 2015-11-12 | 2015-11-12 | METHOD OF TREATMENT OF OPIATES OF OPIATE ABSTINENT SYNDROME |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA107141U (en) |
-
2015
- 2015-11-12 UA UAU201511088U patent/UA107141U/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201690102A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING DIMETHYLFUMATE FOR INTRODUCTION TO LOW DAILY DOSE | |
| EA201401028A1 (en) | PHARMACEUTICAL COMPOSITION, CONTAINING EMAGOGLIFLOZIN AND MEDICINES FOR OBESITY | |
| MY189466A (en) | Methods of modulating drug plasma levels using erythrohydroxybupropion | |
| WO2015054619A3 (en) | Use of a pcsk9 inhibitor to treat hyperlipidemia | |
| EA201591679A1 (en) | METHOD OF NON-TOXIC TREATMENT OF ABSTINENT, CAUSED BY MEDICINE | |
| AR096892A1 (en) | A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | |
| MX373851B (en) | METHODS OF ADMINISTRATION OF PIRFENIDONE TREATMENT. | |
| CL2014002935A1 (en) | Method to treat a human patient with multiple sclerosis with laquinimod, at a daily dose of about 1.2mg; an oral unit dosage form of 1.2 mg of laquinimod and a carrier | |
| MX2018000084A (en) | Pharmaceutical composition containing amlodipine, valsartan, and rosuvastatin. | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| EA201690974A1 (en) | HYDROMORPHONE AND NALOXONE FOR THE TREATMENT OF PAIN AND OPIOID-INITIATED INTESTINAL DYSFUNCTION SYNDROME | |
| EA201491831A1 (en) | CONTAINING PRASONAUTIC STABLE PHARMACEUTICAL COMPOSITIONS WITH IMMEDIATE RELIEF FOR PERIAL INTRODUCTION | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| EA201591603A1 (en) | NEW THERAPEUTIC COMBINATIONS MYRTAZAPINE FOR APPLICATION IN PAIN DISEASES | |
| UA107141U (en) | METHOD OF TREATMENT OF OPIATES OF OPIATE ABSTINENT SYNDROME | |
| UA107142U (en) | METHOD OF TREATMENT OF OPIATES OF OPIATE ABSTINENT SYNDROME | |
| UA111888U (en) | METHOD OF TREATMENT OF OPIATES OF OPIATE ABSTRINENT SYNDROME | |
| RU2016145411A (en) | The combination of brexpiprazole and nalmefene, and its use for the treatment of the syndrome of chemical dependence | |
| UA111923U (en) | METHOD OF TREATMENT OF OPIATES OF OPIATE ABSTRINENT SYNDROME | |
| UA93431U (en) | A METHOD FOR THE USE OF BELASTESIN FOR THE TREATMENT OF MANUFACTURES OF OPIATE ABSTINCENT SYNDROME | |
| RU2013127881A (en) | APPLICATION OF THE PHARMACEUTICAL COMPOSITION BASED ON THE SALT OF QUATERNARY PHOSPHONY AND SUBSTITUTED DINITROBENZOFUROXAN FOR THE TREATMENT OF Pyroplasmosis in Dogs and the Method of Treatment | |
| WO2014023869A3 (en) | Therapeutic use of cd44 inhibitor agents against human acute lymphoblastic leukaemia (all) | |
| RU2013125252A (en) | METHOD FOR MEDICINAL TREATMENT OF PATIENTS IN THE LATE REHABILITATION PERIOD AFTER AORTIC CORONARY BYPASS | |
| UA93361U (en) | METHOD OF TREATMENT OF OPIATES OF OPIATE ABSTRINENT SYNDROME | |
| WO2016193456A3 (en) | Opioid receptor antagonist for use in treating patients with severe constipation |